Table 3.
Detection of chronic HIV-1 infection by the old and new versions of the Alere RDT in plasma specimens from HIV-1-infected patients compared to quantitative PCR, 4G-EIA, and p24 Ag assay
| PCR (c/mL) | Old RDT | New RDT | 4G-EIA | p24CA-EIA (pg/ml) | HIV subtype | ||
|---|---|---|---|---|---|---|---|
| Antibody | p24 Ag | Antibody | p24 Ag | (CMIA index) | |||
| 3060 | + | − | + | − | 963 | − | B |
| 3570 | + | − | + | − | 993 | 19 | B |
| 7550 | + | − | + | − | 982 | − | B |
| 8030 | + | − | + | − | 913 | − | CRF01_AE |
| 26,600 | + | − | + | − | 790 | − | B |
| 131,000 | + | − | + | − | 969 | − | B |
| 1260,000 | + | − | + | − | 188 | 48 | B |
| 7/7 positive (100%) | 7/7 positive (100%) | ||||||
The COBAS Ampliprep/COBAS TaqMan HIV Test v2.0 (PCR), the INNOTEST® HIV Antigen mAb (p24CA-EIA), and the ARCHITECT HIV Ag/Ab Combo (4G-EIA) were performed on plasma specimens before measuring RDT reactivity. Immunoblot reactivity in the specimens was examined via the New LAV Blot I Assay or the INNO-LIA HIV I/II Score. The HIV-1 subtype was determined by Sanger sequencing of the pol/rt region as described previously [39]. + strong reactive; (+) weak reactive; − non-reactive; N/A not acquired